Links for fulltext
(May Require Subscription)
- Publisher Website: 10.7150/ijbs.72709
- Scopus: eid_2-s2.0-85134152870
- PMID: 35874959
- WOS: WOS:000828439300021
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Targeting ACLY efficiently inhibits SARS-CoV-2 replication
Title | Targeting ACLY efficiently inhibits SARS-CoV-2 replication |
---|---|
Authors | Yuen, Terrence Tsz TaiChan, Jasper Fuk WooYan, BingpengShum, Cynthia Cheuk YingLiu, YuanchenShuai, HuipingHou, YuxinHuang, XinerHu, BingjieChai, YueYoon, ChaeminZhu, TianrenzhengLiu, HuanShi, JialuZhang, JinjinCai, Jian PiaoZhang, Anna JinxiaZhou, JieYin, FeifeiYuan, ShuofengZhang, Bao ZhongChu, Hin |
Keywords | ACLY COVID-19 Delta metabolomics Omicron SARS-CoV-2 |
Issue Date | 2022 |
Citation | International Journal of Biological Sciences, 2022, v. 18, n. 12, p. 4714-4730 How to Cite? |
Abstract | The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the biggest public health challenge the world has witnessed in the past decades. SARS-CoV-2 undergoes constant mutations and new variants of concerns (VOCs) with altered transmissibility, virulence, and/or susceptibility to vaccines and therapeutics continue to emerge. Detailed analysis of host factors involved in virus replication may help to identify novel treatment targets. In this study, we dissected the metabolome derived from COVID-19 patients to identify key host factors that are required for efficient SARS-CoV-2 replication. Through a series of metabolomic analyses, in vitro, and in vivo investigations, we identified ATP citrate lyase (ACLY) as a novel host factor required for efficient replication of SARS-CoV-2 wild-type and variants, including Omicron. ACLY should be further explored as a novel intervention target for COVID-19. |
Persistent Identifier | http://hdl.handle.net/10722/315206 |
ISSN | 2023 Impact Factor: 8.2 2023 SCImago Journal Rankings: 2.114 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuen, Terrence Tsz Tai | - |
dc.contributor.author | Chan, Jasper Fuk Woo | - |
dc.contributor.author | Yan, Bingpeng | - |
dc.contributor.author | Shum, Cynthia Cheuk Ying | - |
dc.contributor.author | Liu, Yuanchen | - |
dc.contributor.author | Shuai, Huiping | - |
dc.contributor.author | Hou, Yuxin | - |
dc.contributor.author | Huang, Xiner | - |
dc.contributor.author | Hu, Bingjie | - |
dc.contributor.author | Chai, Yue | - |
dc.contributor.author | Yoon, Chaemin | - |
dc.contributor.author | Zhu, Tianrenzheng | - |
dc.contributor.author | Liu, Huan | - |
dc.contributor.author | Shi, Jialu | - |
dc.contributor.author | Zhang, Jinjin | - |
dc.contributor.author | Cai, Jian Piao | - |
dc.contributor.author | Zhang, Anna Jinxia | - |
dc.contributor.author | Zhou, Jie | - |
dc.contributor.author | Yin, Feifei | - |
dc.contributor.author | Yuan, Shuofeng | - |
dc.contributor.author | Zhang, Bao Zhong | - |
dc.contributor.author | Chu, Hin | - |
dc.date.accessioned | 2022-08-05T10:18:02Z | - |
dc.date.available | 2022-08-05T10:18:02Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | International Journal of Biological Sciences, 2022, v. 18, n. 12, p. 4714-4730 | - |
dc.identifier.issn | 1449-2288 | - |
dc.identifier.uri | http://hdl.handle.net/10722/315206 | - |
dc.description.abstract | The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the biggest public health challenge the world has witnessed in the past decades. SARS-CoV-2 undergoes constant mutations and new variants of concerns (VOCs) with altered transmissibility, virulence, and/or susceptibility to vaccines and therapeutics continue to emerge. Detailed analysis of host factors involved in virus replication may help to identify novel treatment targets. In this study, we dissected the metabolome derived from COVID-19 patients to identify key host factors that are required for efficient SARS-CoV-2 replication. Through a series of metabolomic analyses, in vitro, and in vivo investigations, we identified ATP citrate lyase (ACLY) as a novel host factor required for efficient replication of SARS-CoV-2 wild-type and variants, including Omicron. ACLY should be further explored as a novel intervention target for COVID-19. | - |
dc.language | eng | - |
dc.relation.ispartof | International Journal of Biological Sciences | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | ACLY | - |
dc.subject | COVID-19 | - |
dc.subject | Delta | - |
dc.subject | metabolomics | - |
dc.subject | Omicron | - |
dc.subject | SARS-CoV-2 | - |
dc.title | Targeting ACLY efficiently inhibits SARS-CoV-2 replication | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.7150/ijbs.72709 | - |
dc.identifier.pmid | 35874959 | - |
dc.identifier.pmcid | PMC9305265 | - |
dc.identifier.scopus | eid_2-s2.0-85134152870 | - |
dc.identifier.volume | 18 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 4714 | - |
dc.identifier.epage | 4730 | - |
dc.identifier.isi | WOS:000828439300021 | - |